Basic HTML Version
121
SCIENTIFIC REPORT 2012
Title:
Long-term safety and tolerability profile of REGN727 / SAR236553 in patients
with high cardiovascular risk with hypercholesterolemia not adequately controlled with his
lipid modifying therapy: a randomized, double-blind, placebo-controlled study.
District Attorney:
Sanofi-Aventis SA
Principal Investigator:
Caixàs Pedragós issue.
Title:
Phase III, randomized, double - blind, parallel - group study to evaluate the
efficacy and safety of linagliptin 5 mg compared to placebo, administered orally
at fixed doses in combination with empagliflozin 10 mg or 25 mg for 24 weeks, at
patients with type 2 diabetes mellitus with insufficient glycemic control after 16
weeks of treatment with empagliflozin 10 mg or 25 mg in addition to baseline treatment
with meformin.
District Attorney:
Boehringer Ingelheim España SA
Principal Investigator:
Olga Giménez Palop.
Title:
Test of efficacy and safety of double antiaggregation compared with
combination of oral anticoagulation + double antiplatelet in patients with fibrillation
low-moderate-risk ear subject to the implantation of a coronary stent.
District Attorney:
H. Vall d'Hebrón.
Principal Investigator:
Eduard Bosch Peligero.
Title:
Phase IIIb trial, randomized, double-blind, parallel-group, multicenter, para
to compare the risk of cardiovascular death, myocardial infarction and ischemic stroke in
patients with established peripheral artery disease, treated with ticagrelor vs clopidogrel
(EUCLID).
Promotor
: AstraZeneca.
Principal Investigator:
Antoni Giménez Gaibar.
Title:
Randomized comparative clinical study to evaluate the effectiveness of radiofrequency
(RFO) versus the surgical technique of internal saphenous vein stripping and the CHIVA technique in
the treatment of chronic venous insufficiency in our environment.
District Attorney:
Own.
Principal Investigator:
Elena González Cañas.